Syros Pharmaceuticals Long Term Debt

Syros Pharmaceuticals (SYRS) currently reports a long-term debt of $17M as of September 2024. That compares with $59M in the prior-year period — down 71.7% year over year. Use the charts on this page to explore Syros Pharmaceuticals's long-term debt history and peer comparisons.

Syros Pharmaceuticals's long-term debt decreased from $59M to $17M — a 71.7% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Syros Pharmaceuticals reported $17M in long-term debt as of September 2024. That compares with $59M in the prior-year period — down 71.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $17M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Syros Pharmaceuticals, and consider following SYRS for alerts when major investors trade the stock.

Syros Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $17M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SYRS with unrelated industries.